| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Cerebral | 16 | 2019 | 30 | 4.440 |
Why?
|
| Heme | 11 | 2025 | 72 | 3.500 |
Why?
|
| Chemokine CXCL10 | 11 | 2015 | 38 | 3.150 |
Why?
|
| Malaria | 13 | 2023 | 90 | 2.580 |
Why?
|
| Anemia, Sickle Cell | 10 | 2025 | 187 | 2.260 |
Why?
|
| Malaria, Falciparum | 10 | 2020 | 90 | 1.830 |
Why?
|
| Apoptosis | 13 | 2019 | 1568 | 1.710 |
Why?
|
| Antimalarials | 6 | 2014 | 64 | 1.520 |
Why?
|
| STAT3 Transcription Factor | 4 | 2018 | 102 | 1.360 |
Why?
|
| Neuregulin-1 | 4 | 2022 | 26 | 1.300 |
Why?
|
| Plasmodium falciparum | 8 | 2020 | 144 | 1.190 |
Why?
|
| Endothelial Cells | 7 | 2023 | 329 | 1.080 |
Why?
|
| Biomedical Research | 9 | 2025 | 502 | 1.070 |
Why?
|
| Inflammation | 7 | 2026 | 758 | 1.040 |
Why?
|
| Hydroxyurea | 1 | 2025 | 34 | 0.890 |
Why?
|
| Erythrocytes | 4 | 2020 | 126 | 0.780 |
Why?
|
| Trypanosoma brucei brucei | 5 | 2009 | 82 | 0.760 |
Why?
|
| Humans | 70 | 2026 | 43102 | 0.750 |
Why?
|
| Ghana | 12 | 2022 | 36 | 0.720 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 20 | 0.710 |
Why?
|
| Signal Transduction | 5 | 2018 | 2157 | 0.700 |
Why?
|
| Interleukin-10 | 3 | 2011 | 87 | 0.700 |
Why?
|
| Free Radical Scavengers | 1 | 2021 | 64 | 0.700 |
Why?
|
| Cytokines | 10 | 2026 | 678 | 0.660 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 140 | 0.630 |
Why?
|
| Dietary Supplements | 1 | 2021 | 213 | 0.620 |
Why?
|
| Brain | 9 | 2016 | 1472 | 0.610 |
Why?
|
| Iron | 1 | 2021 | 251 | 0.610 |
Why?
|
| Organoids | 1 | 2019 | 37 | 0.610 |
Why?
|
| Receptors, CXCR3 | 3 | 2019 | 31 | 0.600 |
Why?
|
| Antigens, Protozoan | 3 | 2009 | 74 | 0.590 |
Why?
|
| Pregnancy Complications, Parasitic | 4 | 2011 | 10 | 0.590 |
Why?
|
| Protozoan Proteins | 4 | 2009 | 191 | 0.570 |
Why?
|
| Models, Biological | 2 | 2019 | 712 | 0.560 |
Why?
|
| Brain Injuries | 1 | 2019 | 129 | 0.550 |
Why?
|
| MicroRNAs | 4 | 2026 | 518 | 0.540 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 306 | 0.540 |
Why?
|
| Animals | 40 | 2025 | 16992 | 0.540 |
Why?
|
| Plasmodium berghei | 3 | 2014 | 34 | 0.530 |
Why?
|
| Chemokine CCL5 | 4 | 2007 | 41 | 0.530 |
Why?
|
| Female | 42 | 2026 | 24698 | 0.520 |
Why?
|
| Trypanosomiasis, African | 2 | 2009 | 22 | 0.510 |
Why?
|
| Mice | 16 | 2025 | 6644 | 0.510 |
Why?
|
| Receptors, Chemokine | 4 | 2008 | 72 | 0.510 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2023 | 65 | 0.510 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 749 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 299 | 0.480 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 19 | 0.480 |
Why?
|
| Anemia | 4 | 2016 | 55 | 0.470 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2012 | 3 | 0.460 |
Why?
|
| Gene Expression Regulation | 7 | 2013 | 1070 | 0.460 |
Why?
|
| Cerebellum | 3 | 2005 | 79 | 0.460 |
Why?
|
| HSP70 Heat-Shock Proteins | 3 | 2025 | 57 | 0.460 |
Why?
|
| Disease Models, Animal | 7 | 2025 | 1596 | 0.450 |
Why?
|
| Tsetse Flies | 6 | 1994 | 8 | 0.450 |
Why?
|
| Pyrimethamine | 3 | 2011 | 10 | 0.450 |
Why?
|
| Saliva | 2 | 2022 | 119 | 0.430 |
Why?
|
| Stem Cells | 1 | 2015 | 152 | 0.430 |
Why?
|
| Pregnancy | 9 | 2021 | 1772 | 0.430 |
Why?
|
| Adolescent | 15 | 2021 | 6081 | 0.430 |
Why?
|
| Pregnancy Outcome | 2 | 2012 | 102 | 0.430 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 526 | 0.430 |
Why?
|
| Child, Preschool | 11 | 2016 | 1546 | 0.410 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2013 | 16 | 0.410 |
Why?
|
| Mentors | 5 | 2023 | 145 | 0.400 |
Why?
|
| Encephalitis | 1 | 2014 | 43 | 0.400 |
Why?
|
| Cells, Cultured | 6 | 2019 | 1621 | 0.390 |
Why?
|
| Adenosine Triphosphatases | 3 | 2003 | 83 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 8 | 2018 | 1869 | 0.390 |
Why?
|
| Adult | 20 | 2022 | 13872 | 0.380 |
Why?
|
| Child | 13 | 2016 | 3443 | 0.380 |
Why?
|
| Placenta Previa | 1 | 2012 | 2 | 0.380 |
Why?
|
| Young Adult | 11 | 2021 | 5080 | 0.370 |
Why?
|
| Sulfadoxine | 2 | 2011 | 6 | 0.370 |
Why?
|
| Peptides | 2 | 2026 | 372 | 0.370 |
Why?
|
| Minority Groups | 5 | 2025 | 690 | 0.370 |
Why?
|
| Splenic Diseases | 1 | 2012 | 3 | 0.370 |
Why?
|
| Neuroglia | 2 | 2013 | 133 | 0.360 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 18 | 0.360 |
Why?
|
| Homozygote | 1 | 2012 | 77 | 0.360 |
Why?
|
| Fetal Growth Retardation | 1 | 2012 | 53 | 0.360 |
Why?
|
| Leishmania donovani | 2 | 2003 | 18 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 734 | 0.350 |
Why?
|
| Platelet Factor 4 | 1 | 2011 | 2 | 0.340 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2022 | 47 | 0.340 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 269 | 0.340 |
Why?
|
| Male | 24 | 2025 | 23409 | 0.340 |
Why?
|
| Interleukin-2 | 1 | 2011 | 91 | 0.330 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 78 | 0.330 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 201 | 0.330 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 18 | 0.330 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2025 | 120 | 0.330 |
Why?
|
| Cell Line | 6 | 2016 | 1410 | 0.330 |
Why?
|
| Calcium-Transporting ATPases | 2 | 2009 | 12 | 0.320 |
Why?
|
| HIV Infections | 3 | 2020 | 2586 | 0.320 |
Why?
|
| Sickle Cell Trait | 3 | 2023 | 19 | 0.310 |
Why?
|
| Risk Factors | 9 | 2020 | 3994 | 0.290 |
Why?
|
| Hemolysis | 3 | 2023 | 60 | 0.290 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2010 | 117 | 0.290 |
Why?
|
| Vibrio cholerae | 1 | 2009 | 105 | 0.290 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 10 | 0.280 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 12 | 0.280 |
Why?
|
| Trichomonas vaginalis | 3 | 2009 | 9 | 0.280 |
Why?
|
| C-Reactive Protein | 3 | 2020 | 167 | 0.270 |
Why?
|
| Research Personnel | 4 | 2025 | 206 | 0.270 |
Why?
|
| Genotype | 4 | 2023 | 800 | 0.270 |
Why?
|
| Kidney | 2 | 2025 | 372 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 183 | 0.260 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 3156 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 719 | 0.250 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 263 | 0.250 |
Why?
|
| Host-Parasite Interactions | 3 | 2020 | 79 | 0.250 |
Why?
|
| Cooperative Behavior | 2 | 2025 | 269 | 0.250 |
Why?
|
| Hemoglobins | 3 | 2023 | 113 | 0.240 |
Why?
|
| Plasmodium yoelii | 1 | 2005 | 10 | 0.240 |
Why?
|
| Blood-Brain Barrier | 3 | 2014 | 173 | 0.240 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2019 | 81 | 0.240 |
Why?
|
| Trypanosoma | 4 | 2001 | 8 | 0.240 |
Why?
|
| Helminthiasis | 3 | 2010 | 4 | 0.240 |
Why?
|
| Intestinal Diseases, Parasitic | 3 | 2010 | 5 | 0.240 |
Why?
|
| Cell Differentiation | 3 | 2019 | 638 | 0.230 |
Why?
|
| Case-Control Studies | 3 | 2015 | 1285 | 0.230 |
Why?
|
| Vimentin | 1 | 2025 | 44 | 0.230 |
Why?
|
| Angiopoietin-1 | 3 | 2022 | 4 | 0.220 |
Why?
|
| Angiopoietin-2 | 3 | 2022 | 5 | 0.220 |
Why?
|
| Interinstitutional Relations | 1 | 2025 | 51 | 0.220 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2025 | 59 | 0.220 |
Why?
|
| Leishmania | 3 | 2000 | 20 | 0.220 |
Why?
|
| Trypanosoma cruzi | 2 | 2003 | 157 | 0.210 |
Why?
|
| Mice, Inbred BALB C | 5 | 2009 | 694 | 0.210 |
Why?
|
| Survival Rate | 3 | 2011 | 355 | 0.210 |
Why?
|
| Artemisinins | 2 | 2014 | 19 | 0.200 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 140 | 0.200 |
Why?
|
| Blotting, Western | 6 | 2011 | 883 | 0.200 |
Why?
|
| Genome, Protozoan | 2 | 2000 | 13 | 0.200 |
Why?
|
| Caspase 3 | 4 | 2016 | 227 | 0.200 |
Why?
|
| Leukocytes | 2 | 2014 | 80 | 0.200 |
Why?
|
| Chemokines | 3 | 2012 | 96 | 0.200 |
Why?
|
| Heme Oxygenase-1 | 2 | 2013 | 52 | 0.190 |
Why?
|
| Parasites | 1 | 2023 | 38 | 0.190 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 224 | 0.190 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2001 | 4 | 0.180 |
Why?
|
| RNA, Messenger | 9 | 2009 | 1271 | 0.180 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2009 | 30 | 0.180 |
Why?
|
| Logistic Models | 5 | 2012 | 1009 | 0.180 |
Why?
|
| Organizational Policy | 2 | 2019 | 25 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2011 | 458 | 0.170 |
Why?
|
| Aflatoxin B1 | 2 | 2011 | 3 | 0.170 |
Why?
|
| Public Health | 1 | 2025 | 424 | 0.170 |
Why?
|
| Up-Regulation | 4 | 2011 | 536 | 0.170 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 6 | 0.170 |
Why?
|
| Chagas Disease | 1 | 2001 | 104 | 0.170 |
Why?
|
| ROC Curve | 4 | 2020 | 159 | 0.160 |
Why?
|
| Prevalence | 4 | 2020 | 1612 | 0.160 |
Why?
|
| Trichomonas Infections | 1 | 2000 | 3 | 0.160 |
Why?
|
| HIV | 1 | 2020 | 100 | 0.160 |
Why?
|
| Antibodies, Protozoan | 3 | 2009 | 82 | 0.160 |
Why?
|
| Umbilical Cord | 1 | 2019 | 14 | 0.160 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 32 | 0.160 |
Why?
|
| Membrane Proteins | 3 | 2013 | 561 | 0.150 |
Why?
|
| Gene Expression | 3 | 2016 | 701 | 0.150 |
Why?
|
| Repressor Proteins | 3 | 2008 | 273 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 652 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2025 | 1003 | 0.150 |
Why?
|
| Parasitemia | 2 | 2016 | 13 | 0.150 |
Why?
|
| India | 5 | 2011 | 108 | 0.150 |
Why?
|
| Peer Review, Research | 1 | 2018 | 15 | 0.150 |
Why?
|
| Caspases | 2 | 2013 | 148 | 0.150 |
Why?
|
| Education | 1 | 2019 | 60 | 0.140 |
Why?
|
| Teaching | 1 | 2019 | 59 | 0.140 |
Why?
|
| Prognosis | 3 | 2011 | 861 | 0.140 |
Why?
|
| Leadership | 1 | 2019 | 86 | 0.140 |
Why?
|
| Hemangioendothelioma | 1 | 2018 | 2 | 0.140 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 229 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2018 | 89 | 0.140 |
Why?
|
| Binding Sites | 2 | 2025 | 671 | 0.140 |
Why?
|
| Chemokines, CC | 3 | 2007 | 55 | 0.140 |
Why?
|
| Blood Proteins | 2 | 2016 | 77 | 0.140 |
Why?
|
| Coculture Techniques | 1 | 2018 | 109 | 0.140 |
Why?
|
| Mice, Transgenic | 3 | 2022 | 665 | 0.130 |
Why?
|
| Molecular Sequence Data | 4 | 2013 | 1542 | 0.130 |
Why?
|
| Genes, Protozoan | 2 | 2009 | 18 | 0.130 |
Why?
|
| Base Sequence | 3 | 2013 | 983 | 0.130 |
Why?
|
| DNA, Protozoan | 3 | 2003 | 26 | 0.130 |
Why?
|
| Pregnancy Proteins | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cell Fusion | 1 | 2016 | 19 | 0.130 |
Why?
|
| Stroke | 2 | 2012 | 340 | 0.130 |
Why?
|
| Hemeproteins | 1 | 2016 | 15 | 0.130 |
Why?
|
| Galectin 3 | 1 | 2016 | 30 | 0.130 |
Why?
|
| Receptors, CCR5 | 3 | 2006 | 64 | 0.130 |
Why?
|
| Trophoblasts | 1 | 2016 | 33 | 0.120 |
Why?
|
| Galectins | 1 | 2016 | 30 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2016 | 79 | 0.120 |
Why?
|
| Protein Binding | 2 | 2025 | 1082 | 0.120 |
Why?
|
| United States | 6 | 2025 | 5205 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 704 | 0.120 |
Why?
|
| Epithelial Cells | 2 | 2018 | 434 | 0.120 |
Why?
|
| Placenta | 1 | 2016 | 117 | 0.120 |
Why?
|
| Trichomonas Vaginitis | 2 | 2009 | 5 | 0.120 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2012 | 9 | 0.110 |
Why?
|
| Drug Resistance | 2 | 2009 | 96 | 0.110 |
Why?
|
| Receptors, CCR3 | 2 | 2005 | 10 | 0.110 |
Why?
|
| Trypanosoma congolense | 2 | 1994 | 3 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1124 | 0.110 |
Why?
|
| Endothelium | 1 | 2014 | 28 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2011 | 104 | 0.100 |
Why?
|
| Middle Aged | 7 | 2020 | 12222 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 1723 | 0.100 |
Why?
|
| Digestive System | 2 | 1994 | 21 | 0.100 |
Why?
|
| Infant | 4 | 2016 | 1175 | 0.100 |
Why?
|
| Janus Kinases | 1 | 2013 | 23 | 0.100 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 12 | 0.100 |
Why?
|
| Transcription, Genetic | 5 | 2003 | 592 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 2 | 2005 | 83 | 0.100 |
Why?
|
| Cell Count | 1 | 2013 | 145 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2020 | 2544 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 173 | 0.100 |
Why?
|
| Pyrroles | 1 | 2013 | 72 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2013 | 150 | 0.100 |
Why?
|
| Fetal Death | 1 | 2012 | 18 | 0.090 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 28 | 0.090 |
Why?
|
| Eclampsia | 1 | 2012 | 12 | 0.090 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 33 | 0.090 |
Why?
|
| Hemoglobin, Sickle | 2 | 2023 | 11 | 0.090 |
Why?
|
| Maternal Mortality | 1 | 2012 | 26 | 0.090 |
Why?
|
| Nucleic Acid Conformation | 1 | 2013 | 154 | 0.090 |
Why?
|
| Splenectomy | 1 | 2012 | 9 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2013 | 368 | 0.090 |
Why?
|
| Birth Weight | 1 | 2012 | 95 | 0.090 |
Why?
|
| Gestational Age | 1 | 2012 | 200 | 0.090 |
Why?
|
| Developing Countries | 2 | 2019 | 113 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 455 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2011 | 34 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2011 | 68 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2011 | 150 | 0.090 |
Why?
|
| Agglutinins | 1 | 1990 | 2 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 62 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2014 | 373 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2011 | 38 | 0.080 |
Why?
|
| Peptide Hydrolases | 1 | 1990 | 44 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 68 | 0.080 |
Why?
|
| E-Selectin | 2 | 2007 | 23 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 638 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 611 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2013 | 986 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2026 | 2676 | 0.080 |
Why?
|
| Staurosporine | 2 | 2008 | 38 | 0.080 |
Why?
|
| Disease Management | 1 | 2011 | 70 | 0.080 |
Why?
|
| Chitin | 1 | 1990 | 20 | 0.080 |
Why?
|
| Stillbirth | 1 | 2010 | 20 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 4 | 2009 | 515 | 0.080 |
Why?
|
| Chloroquine | 1 | 2009 | 19 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 209 | 0.080 |
Why?
|
| RNA Splicing | 2 | 1999 | 41 | 0.080 |
Why?
|
| Viral Load | 1 | 2011 | 348 | 0.080 |
Why?
|
| Protozoan Vaccines | 1 | 2009 | 16 | 0.080 |
Why?
|
| Endopeptidases | 2 | 2004 | 64 | 0.080 |
Why?
|
| Interleukin-8 | 2 | 2007 | 74 | 0.080 |
Why?
|
| Cobalt Radioisotopes | 1 | 1989 | 1 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2013 | 876 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 75 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 863 | 0.070 |
Why?
|
| Toxoplasmosis, Animal | 1 | 2008 | 1 | 0.070 |
Why?
|
| Granulosa Cells | 2 | 2006 | 44 | 0.070 |
Why?
|
| Lung | 1 | 2012 | 492 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 166 | 0.070 |
Why?
|
| Receptors, GABA-A | 1 | 2009 | 65 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2008 | 15 | 0.070 |
Why?
|
| Dietary Proteins | 1 | 2008 | 35 | 0.070 |
Why?
|
| Urban Population | 2 | 2016 | 374 | 0.070 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2008 | 34 | 0.070 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2008 | 20 | 0.070 |
Why?
|
| Spinal Cord | 1 | 2009 | 114 | 0.070 |
Why?
|
| Virion | 1 | 1988 | 75 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 458 | 0.070 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2007 | 15 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2007 | 17 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 211 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 63 | 0.070 |
Why?
|
| Ovary | 2 | 2008 | 113 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2011 | 549 | 0.070 |
Why?
|
| Temperature | 2 | 2004 | 313 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2008 | 154 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 165 | 0.070 |
Why?
|
| Immunoassay | 1 | 2007 | 74 | 0.070 |
Why?
|
| Mitochondria | 2 | 2008 | 523 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2008 | 346 | 0.060 |
Why?
|
| Receptors, CCR1 | 1 | 2005 | 8 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2009 | 430 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2026 | 968 | 0.060 |
Why?
|
| Carrier State | 1 | 2006 | 33 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 1 | 2006 | 34 | 0.060 |
Why?
|
| Pneumococcal Infections | 1 | 2006 | 33 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2005 | 51 | 0.060 |
Why?
|
| Surface Plasmon Resonance | 1 | 2025 | 42 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 384 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 294 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 31 | 0.060 |
Why?
|
| Mycotoxicosis | 1 | 2004 | 1 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2005 | 97 | 0.060 |
Why?
|
| Aflatoxins | 1 | 2004 | 8 | 0.060 |
Why?
|
| Time Factors | 2 | 2008 | 1857 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 310 | 0.050 |
Why?
|
| Follicular Atresia | 1 | 2004 | 6 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2005 | 132 | 0.050 |
Why?
|
| Hemopexin | 1 | 2023 | 3 | 0.050 |
Why?
|
| Body Composition | 1 | 2005 | 159 | 0.050 |
Why?
|
| 14-3-3 Proteins | 1 | 2023 | 21 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 138 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 98 | 0.050 |
Why?
|
| Brain Stem | 1 | 2004 | 52 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 415 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 290 | 0.050 |
Why?
|
| Ovarian Follicle | 1 | 2004 | 44 | 0.050 |
Why?
|
| Cities | 1 | 2004 | 79 | 0.050 |
Why?
|
| Hemoglobin A | 1 | 2023 | 4 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2004 | 109 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 40 | 0.050 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2003 | 28 | 0.050 |
Why?
|
| Prejudice | 1 | 2004 | 116 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2003 | 181 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 196 | 0.050 |
Why?
|
| Plasmodium | 1 | 2022 | 16 | 0.050 |
Why?
|
| Liposomes | 1 | 2023 | 132 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 47 | 0.050 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2002 | 7 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.050 |
Why?
|
| Insect Vectors | 2 | 1994 | 27 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 291 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2001 | 150 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 187 | 0.040 |
Why?
|
| Social Class | 1 | 2004 | 291 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 12 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 2012 | 87 | 0.040 |
Why?
|
| Proton Pumps | 1 | 2000 | 2 | 0.040 |
Why?
|
| Proton-Translocating ATPases | 1 | 2000 | 17 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 66 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 2 | 2012 | 70 | 0.040 |
Why?
|
| Cell Movement | 1 | 2004 | 655 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2000 | 25 | 0.040 |
Why?
|
| Antitrichomonal Agents | 1 | 2000 | 2 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2000 | 4 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 2000 | 13 | 0.040 |
Why?
|
| Urethritis | 1 | 2000 | 2 | 0.040 |
Why?
|
| Microscopy, Electron | 3 | 1990 | 210 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2000 | 68 | 0.040 |
Why?
|
| Metronidazole | 1 | 2000 | 16 | 0.040 |
Why?
|
| RNA, Protozoan | 1 | 1999 | 13 | 0.040 |
Why?
|
| Geography | 2 | 2004 | 110 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 1019 | 0.040 |
Why?
|
| Poly A | 1 | 1999 | 33 | 0.040 |
Why?
|
| Exons | 1 | 1999 | 92 | 0.040 |
Why?
|
| South America | 1 | 2019 | 24 | 0.040 |
Why?
|
| Professional Competence | 1 | 2019 | 42 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 82 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 98 | 0.040 |
Why?
|
| Writing | 1 | 2018 | 42 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 111 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 56 | 0.040 |
Why?
|
| Cultural Diversity | 2 | 2014 | 193 | 0.030 |
Why?
|
| Food Contamination | 2 | 2010 | 57 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 240 | 0.030 |
Why?
|
| Adenoviridae | 2 | 2008 | 62 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 259 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 518 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2016 | 11 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 13 | 0.030 |
Why?
|
| Rats | 4 | 2009 | 3735 | 0.030 |
Why?
|
| Species Specificity | 2 | 1994 | 286 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 69 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2012 | 1600 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 1092 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 934 | 0.030 |
Why?
|
| Population Density | 1 | 1994 | 38 | 0.030 |
Why?
|
| Kenya | 1 | 1994 | 58 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2005 | 59 | 0.020 |
Why?
|
| Rural Population | 1 | 2016 | 373 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 9 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2009 | 1234 | 0.020 |
Why?
|
| Phylogeny | 2 | 2009 | 769 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 2011 | 6 | 0.020 |
Why?
|
| Hepatitis C Antibodies | 1 | 2011 | 10 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2011 | 13 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2011 | 51 | 0.020 |
Why?
|
| Psychodidae | 1 | 1991 | 3 | 0.020 |
Why?
|
| Agglutination | 1 | 1990 | 1 | 0.020 |
Why?
|
| Freezing | 1 | 1990 | 17 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1990 | 25 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2011 | 74 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 201 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 575 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1990 | 168 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1990 | 197 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 1766 | 0.020 |
Why?
|
| Trypanosomatina | 1 | 1990 | 4 | 0.020 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2009 | 15 | 0.020 |
Why?
|
| Gels | 1 | 1990 | 45 | 0.020 |
Why?
|
| Diptera | 1 | 1990 | 11 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 8214 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 61 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 53 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 321 | 0.020 |
Why?
|
| Chitosan | 1 | 1990 | 53 | 0.020 |
Why?
|
| Point Mutation | 1 | 2009 | 98 | 0.020 |
Why?
|
| Hygiene | 1 | 2009 | 14 | 0.020 |
Why?
|
| Pest Control, Biological | 1 | 1989 | 9 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 2853 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1989 | 27 | 0.020 |
Why?
|
| Isoenzymes | 1 | 1990 | 168 | 0.020 |
Why?
|
| Photomicrography | 1 | 2009 | 3 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 2009 | 5 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 23 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1990 | 238 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2009 | 37 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 587 | 0.020 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2008 | 9 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2008 | 24 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 138 | 0.020 |
Why?
|
| Toxoplasma | 1 | 2008 | 12 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2009 | 93 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 74 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2008 | 86 | 0.020 |
Why?
|
| Arginase | 1 | 2008 | 15 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 465 | 0.020 |
Why?
|
| G1 Phase | 1 | 2008 | 31 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 34 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2009 | 283 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2008 | 98 | 0.020 |
Why?
|
| Arginine | 1 | 2008 | 75 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 147 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 165 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 256 | 0.020 |
Why?
|
| Weight Gain | 1 | 2008 | 139 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 695 | 0.020 |
Why?
|
| Phosphatidylserines | 1 | 2006 | 22 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2006 | 48 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2006 | 90 | 0.020 |
Why?
|
| Meningitis, Bacterial | 1 | 2005 | 11 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 436 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2006 | 47 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2005 | 39 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 32 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 532 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 307 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 511 | 0.010 |
Why?
|
| Cell Survival | 1 | 2008 | 945 | 0.010 |
Why?
|
| Receptors, CCR | 1 | 2004 | 26 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 49 | 0.010 |
Why?
|
| Chlamydia trachomatis | 1 | 2005 | 70 | 0.010 |
Why?
|
| Chlamydia muridarum | 1 | 2005 | 104 | 0.010 |
Why?
|
| Cloning, Organism | 1 | 2004 | 22 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 249 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2005 | 144 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 216 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 247 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 269 | 0.010 |
Why?
|
| Fertilization in Vitro | 1 | 2004 | 57 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 508 | 0.010 |
Why?
|
| Prostate | 1 | 2004 | 155 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 240 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 411 | 0.010 |
Why?
|
| Oocytes | 1 | 2004 | 149 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 157 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 195 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 378 | 0.010 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2002 | 7 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2002 | 75 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 1035 | 0.010 |
Why?
|
| Life Style | 1 | 2004 | 334 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 1263 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2002 | 108 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 2000 | 19 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2000 | 16 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2004 | 363 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 199 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 272 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 314 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 321 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2000 | 95 | 0.010 |
Why?
|
| Monocytes | 1 | 2000 | 277 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 1180 | 0.010 |
Why?
|
| Trypsin | 1 | 1994 | 40 | 0.010 |
Why?
|
| Swine | 1 | 1994 | 212 | 0.010 |
Why?
|
| Cattle | 1 | 1990 | 498 | 0.000 |
Why?
|